NextGen Healthcare, Inc. NXGN recently announced that FPA Women’s Health deployed its integrated NextGen Patient Experience Platform to offer continuity of care during the COVID-19 pandemic.Notably, FPA Women’s Health is a mid-sized specialty medical group committed to women’s healthcare.This is likely to bolster NextGen’s presence in the global healthcare information technology (HCIT) space.More on the DevelopmentWithin the NextGen Patient Experience Platform, FPA Women’s Health leveraged NextGen Virtual Visits to continue treating patients with a wide range of services, such as contraceptive counseling and refills, UTI or STI treatment and the follow-ups on lab results. Moreover, the clinic deployed NextGen Patient Self-Scheduling to make after-hours scheduling convenient and more accessible to staff and patients during the ongoing global health emergency.Integration with the NextGen Enterprise EHR for patient self-scheduling and virtual visit solutions lessened the risk of duplicative chart problems, which is a major challenge.Notable DevelopmentsIn September 2020, management announced that the company’s next-generation behavioral health suite is available. Backed by a renowned electronic health record (EHR) and practice management system, this health arm is the industry’s only platform that amalgamates physical, behavioral and oral health into an all-inclusive package of a single software solution.Earlier in August, Virginia Cardiovascular Specialists, the largest private cardiology practice in Central Virginia, implemented NextGen Virtual Visits to extend care and treatment for non-urgent visits utilizing telehealth during the pandemic situation.Market ProspectsPer a recent Verify Markets report, the virtual healthcare market is expected to reach a worth of more than $3.5 billion by 2022, seeing a CAGR of 49.8% during the forecast period.Price PerformanceShares of this currently Zacks Rank #4 (Sell) company have gained 14.6% in a year’s time compared with the industry’s growth of 26.8%.Key PicksSome better-ranked stocks from the broader medical space are McKesson Corporation MCK, DaVita Inc DVA and IDEXX Laboratories IDXX,each carrying a Zacks Rank #2 (Buy), presently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.McKesson has a projected long-term earnings growth rate of 6.6%.DaVita has an expected long-term earnings growth rate of 18.3%.IDEXX has an estimated long-term earnings growth rate of 15.8%.5 Stocks Set to DoubleEach was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report NEXTGEN HEALTHCARE, INC (NXGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research